https://www.selleckchem.com/pr....oducts/gsk-j4-hcl.ht
t-enhanced CT, which could be helpful in selecting patients who are more likely to respond to therapy, and with a longer survival. • To achieve the best results of treatment with sorafenib in advanced HCC, a strict selection of patients is needed. • New radiologic parameters predictive of the response to sorafenib would be essential. • Volume of enhancement of disease (VED) is a novel radiologic parameter obtained by contrast-enhanced CT, which could be helpful in selecting patients who are more likely to respond to therapy, and with
Like
Comment
Share
